|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.16 - 31.16|
|52 Week Range||27.58 - 44.60|
|Beta (3Y Monthly)||0.57|
|PE Ratio (TTM)||25.86|
|Forward Dividend & Yield||0.29 (1.01%)|
|1y Target Est||N/A|
ADR: IPSEY), a global specialty-driven biopharmaceutical group, today will host an Investor Day in Paris to present a comprehensive corporate update, with a focus on its advancing R&D pipeline. David Meek, Chief Executive Officer of Ipsen stated: “The business momentum of Ipsen is strong, delivering industry-leading top-line growth and investing to build an innovative and sustainable pipeline. “Ipsen currently has five new chemical entities in clinical development, nine significant regulatory submissions planned from 2019 to 2022 and several mid-to-late-stage program readouts in the coming months.
The structure's credit enhancement is quantified by the maximum deterioration in property value that the securities are able to withstand under various stress scenarios without causing an increase in the expected loss for various rating levels. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over 100%. For example, th...
ADR: IPSEY) and Clementia Pharmaceuticals (CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO).
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it prac...
ADR: IPSEY) announced today that its 2018 Registration Document has been filed with the French “Autorité des Marchés Financiers” (AMF) on 26 March 2019 and registered under the number D.19-0205. Copies are also available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt – France. Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care.
ADR: IPSEY) today announced that they are looking forward to revealing 17 presentations that detail their research into neuroendocrine tumors (NETs) at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference, which is taking place in Barcelona, Spain between 6th-8th March 2019. Input from patients and their caregivers, as well as nurses and other healthcare professionals, was used to design a new pre-filled syringe1 that was submitted to the European Union as a type II variation via a work-sharing procedure with HPRA (Ireland) as the reference country. “It is our mission to ensure patients continue to receive optimized care as they navigate the challenges of living with NETs and acromegaly,” said Sotirios Stergiopoulos, Chief Medical Officer at Ipsen.
French healthcare company Ipsen agreed to buy Clementia Pharmaceuticals Inc. Ipsen said it would pay $25 a share in cash initially for Clementia, plus a contingent value right of $6 a share upon Food and Drug Administration approval of Clementia's palovarotene drug for the treatment of multiple osteochondromas, a rare bone disorder. The companies said the initial cash consideration represents a premium of 77% to Clementia's 30-day volume-weighted average stock price.
Swiss pharma giant Roche Holdings AG Basel ADR (OTC: RHHBY) announced early Monday a deal to buy U.S.-based gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) for $114.50 per share in cash, or a total equity value of $4.8 billion, including about $500 million of net cash expected at close. The per share value represents a 122.07-percent premium over Spark's Friday closing price of $51.56. Roche will commence a tender offer to acquire all outstanding shares of Spark, and upon completion will acquire the remaining untendered shares at the same price through a second step merger.
French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion (£1 billion), the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases. Ipsen's shares dipped 0.6 percent after the company said the takeover would initially weigh on margins due to the costs of forthcoming trials for Clementia products, but it hoped they would recover later on. Ipsen said it would buy all of Clementia's shares for $25 each in cash upfront and offer a contingent value right (CVR) purchase of $6.00 per share, giving a total transaction value of up to $1.31 billion.
French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases. Ipsen's shares dipped 0.6 percent after the company said the takeover would initially weigh on margins due to the costs of forthcoming trials for Clementia products, but it hoped they would recover later on. Ipsen said it would buy all of Clementia's shares for $25 each in cash upfront and offer a contingent value right (CVR) purchase of $6.00 per share, giving a total transaction value of up to $1.31 billion.
Ipsen said it would initially pay $25 a share in cash for Clementia, and a further $6 a share contingent on Clementia’s palovarotene drug receiving FDA approval for the treatment of a rare bone disorder. The deal will boost Ipsen’s participation in the treatment of rare diseases and bulk up its pipeline of future treatments, the company said. Ipsen will finance the transaction through existing cash and credit lines, which will significantly increase its net debt and have a dilutive effect on net income and operating margins.
PARIS & MONTRÉAL-- -- Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 Acquisition to transform Ipsen’s Rare Disease portfolio by leveraging Clementia’s expertise and Ipsen’s global commercial footprint to provide life-altering treatments to patients with ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In this article I am going toRead More...
ADR: IPSEY) today presents at TOXINS, results from an international survey revealing the hidden burden of spasticity and the need for longer periods of symptomatic relief1. Affecting 12 million people around the world2, spasticity is one of the most common and disabling conditions associated with neurological diseases in adults (stroke, traumatic brain, etc.) and characterised by an abnormal increase in muscle tone or stiffness3. A survey of 615 respondents from 6 participating countries confirms that spasticity has a profound impact on ability to perform everyday tasks, including the ability to carry items, walk, and drive and reduces independence overall.
Results of the first in-human study of a recombinant neurotoxin are being presented at the TOXINS International Conference in Copenhagen. Ipsen’s recombinant BoNT serotype E (rBoNT-E) was investigated in a phase I study that demonstrated its safety and tolerability profile in healthy volunteers1.
David Meek became the CEO of Ipsen S.A. (EPA:IPN) in 2016. First, this article will compare CEO compensation with compensation at other large companies. Then we'll look at a snap Read More...
The size of Ipsen S.A. (EPA:IPN), a €9.7b large-cap, often attracts investors seeking a reliable investment in the stock market. Doing business globally, large caps tend to have diversified revenue Read More...